Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · View financials
Decision snapshot: SRPT stock price vs QMCO: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at QMCO's multiple
Needs QMCO P/S.
Implied fair value · at SRPT's multiple
Needs SRPT P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SRPT FY 2025 (ended Dec 31, 2025) · QMCO FY 2026 (ended Mar 31, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
SAREPTA THERAPEUTICS, INC. · implied price per share
Bear
-$43.23
Base
-$50.86
Bull
-$58.48
QUANTUM CORP /DE/ · implied price per share
Bear
-$17.54
Base
-$20.63
Bull
-$23.73
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.82x
-0.73x
Net debt / EBITDA
Leverage against operating earnings
0.01x
-1.82x
Cash and equivalents
Liquid reserves on the balance sheet
$939.65M
$15.57M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$934.46M
$144.85M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe SRPT can improve margins and sustain its 15.6% revenue growth without further balance-sheet deterioration, then holding or accumulating modestly makes sense because the stock is near fair value at $15.00 versus an implied $14.61 and within its historical band.
SRPT’s implied price of $14.61 is essentially in line with the current price of $15.00, implying just -2.6% downside. On the provided QMCO framework, SRPT is near the middle of its historical band and not offering a meaningful valuation discount.
Supporting Metrics
